M-Eloxyn (Canada)

Step 2⁽¹⁾. Place the circular plastic insert into the neck of the bottle and push down until securely in place. Once in place the insert will not need to be removed.

Step 3.

Replace the cap on the bottle and shake it well. Take off the bottle cap and attach the dosing syringe to the bottle by gently pushing the end into the hole.

Step 4.

Turn the bottle with the syringe in place upside down and slowly withdraw the plunger until the required dose is evident.

Step 5. Turn the bottle/syringe the right way up and with a twisting movement separate the syringe from the bottle.

Step 6. Push the plunger until all contents of the syringe have been dispensed onto the food.

⁽¹⁾ Not applicable if the circular plastic insert is already installed.

A clinical response is normally seen within 3 to 4 days. Treatment should be discontinued after 10 days at the latest if no clinical improvement is apparent.

Contraindications

M-Eloxyn 1.5 mg/mL oral suspension for dogs should not be administered if gastric or intestinal ulceration or bleeding is suspected; if there is evidence of cardiac, hepatic or renal disease; or if there is evidence of a haemorrhagic disorder or individual hypersensitivity to the product. Do not administer concurrently, other steroidal or nonsteroidal anti-inflammatory drugs (NSAIDs), aminoglycoside antibiotics or anti-coagulant agents. Pre-treatment with other steroidal or nonsteroidal anti-inflammatory drugs (NSAIDS) may result in additional or increased effects. Depending on the pharmacokinetic properties of the products used previously, an appropriate treatment-free period with such drugs should be observed before commencement of treatment.

Do not use if there is evidence of dehydration, hypovolemia or hypotension, because of the increased risk of renal injury caused by the destruction of protective prostaglandins secreted by the kidneys in this risk situation.

Cautions: Not approved for use in cats. M-Eloxyn 1.5 mg/mL oral suspension for dogs should not be administered to breeding, pregnant or lactating dogs. Do not exceed the stated dose. In case of overdosing, symptomatic treatment should be initiated.

Animals being treated with meloxicam should be monitored for the occurrence of side effects as susceptibility varies with the individual.

If vomiting, inappetence, lethargy, diarrhea, increased drinking, increased or inappropriate urination or other suspected adverse reactions occur, IMMEDIATELY discontinue treatment and seek the advice of a veterinarian (see Adverse Reactions).

As for all NSAIDs, use in debilitated aged animals may involve additional risk. If use in such animals cannot be avoided, a reduced dosage and careful clinical management may be required. Safety of meloxicam in very young puppies has not been evaluated.

Warnings: Keep out of reach of children.

People with known hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) should not handle this product.

Pregnant women should not handle this product unless adequate exposure protection can be assured.

Caution should be taken to avoid accidental ingestion and contact with eyes.

This product can cause eye irritation. In case of contact with the eyes, immediately rinse thoroughly with water.

Adverse Reactions

Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhea, apathy or polyuria and polydipsia associated with renal failure have occasionally been reported. These adverse reactions are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.

Although all adverse reactions are not reported, the following adverse reaction information is based on voluntary reporting by veterinarians and pet owners/caregivers. It should be noted that suspected adverse reactions listed here reflect reporting, not causality. The categories of adverse reactions are listed in decreasing order of frequency by body system. In rare cases, death has been associated with some of these adverse reactions:

Digestive tract disorders: vomiting, diarrhea, melena, hematemesis, gastric ulcer.

Systemic disorders: anorexia, lethargy, jaundice.

Renal and urinary disorders: acute renal failure.

Investigations: elevated creatinine and BUN, elevated liver enzymes.

Neurological disorders: ataxia, seizure, trembling.

Behavioural disorders: behavioural disorder, hyperactivity.

Skin and appendages disorders: pruritus, eczema, alopecia local, moist dermatitis (hot spots), allergic dermatitis.

Immune system disorders: urticaria, immune mediated hemolytic anemia, immune mediated thrombocytopenia.

Information for Dog Owners: M-Eloxyn 1.5 mg/mL oral suspension for dogs (meloxicam) is a nonsteroidal anti-inflammatory drug (NSAID) and as with others in this class, adverse reactions may occur in treated dogs. The most common adverse reactions reported involve the gastrointestinal tract and the kidneys and usually occur within the first week of treatment. Typical symptoms include loss of appetite, vomiting, diarrhea, dark stools and depression, increased drinking and increase or inappropriate urination. It is important in these situations to discontinue treatment IMMEDIATELY and contact your veterinarian. In most cases, the adverse reactions are transient and disappear after termination of treatment but in rare instances may be serious especially if treatment is not discontinued. Shake well before use.

Safety: The safety profile of meloxicam has been evaluated in well controlled target animal safety studies in dogs. Dogs treated with placebo, 1X, 3X and 5X label dosages were closely monitored over a 180 day (26 week period). The study determined that there were no drug related adverse reactions on clinical observations, normal body weight gain, food consumption, physical and ophthalmic examinations, clotting times, mucosal bleeding times or on a panel of clinical pathology parameters monitored throughout the study.

Storage

Presentation: Plastic bottles of 15, 42, 100 or 200 mL supplied with a measuring syringe.

Zoetis^® and M-Eloxyn are registered trademarks of Zoetis or its licensors.

Zoetis Canada Inc., Kirkland QC H9H 4M7

LB8329

1721-11-1

July 2023

CPN: 1198488.3